Our genomes are filled with errors that were once impossible to correct. But in CRISPR, we finally found an extraordinarily ...

A bacterial defense system called SPARDA employs kamikaze-like tactics to protect cells and could be useful in future ...

Aurora Therapeutics, cofounded by Nobel Prize–winning scientist Jennifer Doudna, plans to use gene editing and a new FDA ...

CRISPR Therapeutics analysis: long-term upside despite volatility. Track Casgevy ramp, pipeline milestones & cash runway.

Innovative research into the gene-editing tool targets influenza’s ability to replicate—stopping it in its tracks.

CRISPR Therapeutics AG (CRSP) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to ...

Picture CRISPR-Cas9, a gene editing technology, as a GPS-guided scalpel: gRNA directs the Cas9 enzyme, a protein that cuts ...

Infection with the pathogenic yeast fungus Candida auris (C. auris) can wreak havoc on the health of hospital patients and ...

Genetic disorders occur due to alterations in the primary genetic material—deoxyribonucleic acid (DNA)—of an organism.

The need to change regulations around gene-editing treatments was endorsed in November by the head of the US Food and Drug ...

Earlier this month, CRISPR Therapeutics presented at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, ...

In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $54.21, marking a -4.71% move from the previous day. The stock's performance was behind the S&P 500's daily gain of 0.26%. At the ...